After-Hours Movers Tuesday: Vertex Pharmaceuticals Inc., Orexigen Therapeutics Inc.

TubeMogul Inc.

gained 13 percent to $17.50 in late trading Tuesday after the enterprise software company for digital branding posted first-quarter earnings and raised its guidance. Hortonworks Inc.

rose 10 percent to $24 in the extended session. The data management platform provider said first-quarter revenue increased 167 percent to $22.8 million. New Relic Inc.

traded up 8 percent to $35.50 after the bell. The cloud-base analytics platform provider said fiscal fourth-quarter revenue grew 68 percent. Opower Inc.

ticked up 5 percent to $11.25 in the late session. The provider of cloud-based software for the utility industry said quarterly revenue gained 17 percent. Vertex Pharmaceuticals Inc.

gained more than 5 percent to $132.89 in the late session on news that a regulatory advisory committee recommended approval of its cystic fibrosis treatment called Orkambi. An FDA decision is expected by July 5. Zillow Group Inc.

ticked up about 2 percent following the bell Tuesday to $99.60. The company posted first-quarter pro forma revenue growth of 35 percent and reiterated its full-year outlook. Orexigen Therapeutics Inc.

tumbled more than 13 percent to $5.15 in after-hours trading. The company terminated a cardiovascular outcomes trial of its anti-obesity drug Contravene, from which interim results were inadvertently released earlier this year. The trial is not being terminated because of a finding of superiority or harm. An additional trial is expected to be completed in 2020. Star Bulk Carriers Corp.

declined 10 percent to $3.40 after the Greek maritime shipper announced a $150 million public offering. Vivint Solar Inc.

declined about 8 percent to $13.80 in late trading. The residential solar company posted first quarter results and an outlook. Exar Corp.

lost about 5 percent in the extended session, trading at $9.55, after the integrated circuit maker said its market softened in the recent quarter and it hired financial advisors to review alternatives.